SynthesisFrontiers in pharmacology2025
Effects of anti-osteoporotic drugs in patients with chronic kidney disease: a systemic review and network meta-analysis of bone mineral density, clinical fracture rate and renal function.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This systematic review and network meta-analysis investigated the effects of various anti-osteoporotic drugs (AODs) on bone mineral density (BMD), estimated glomerular filtration rate (eGFR), and clinical fracture rate in patients with chronic kidney disease (CKD) and osteoporosis. Methods and results: We searched for relevant studies in PubMed, Embase, and Web of Science and included randomized controlled trials with any following outcomes of interest: clinical fracture rate, BMD, and eGFR. The effectiveness of different AODs was assessed by random-effects model network meta-analysis and ranked on the basis of P-scores. A total of seven studies involving 18,503 patients were included. Three AODs: sclerostin inhibitors, bisphosphonates and parathyroid hormone (PTH) analogs were associated with mild but significantly increased BMD at the lumbar spine, total hip, and femoral neck. In addition, sclerostin inhibitors (relative risk; RR:0.38, 95% CI: 0.23-0.62), bisphosphonates (RR:0.53, 95% CI: 0.30-0.92), denosumab (RR:0.58, 95% CI: 0.52-0.66), and PTH analogs (RR:0.68, 95% CI: 0.55-0.86) effectively reduced clinical fracture rates. AODs did not significantly affect eGFRs. Among the five AODs, according to P-score ranking, sclerostin inhibitors were the most effective in reducing clinical fracture risk, and PTH analogs resulted in the most favorable improvement in BMD. The five AODs had no significant effect on eGFR. Conclusion: We demonstrated that bisphosphonates, PTH analogs, denosumab, and sclerostin inhibitors can reduce clinical fracture risk in CKD patient's osteoporosis but with low to very low confidence of evidence. In clinical practice, sclerostin inhibitors and PTH analogs could result in the highest reduction in clinical fracture risk and improvement in BMD, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.